This Post Was Syndicated Under License Via QuoteMedia
VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF) today announced that it will begin an observational study on the use of cannabinoids as therapy for chronic pain. A group of well-known pain specialists will lead the study, taking place in Melbourne, Australia, which expects to provide long-term (24 month) data in order to evaluate the efficacy of medical cannabis in treating pain and further support development of VIVO’s portfolio of medical cannabis products. VIVO is funding the effort in the form of a research grant to its partner in the study, Australian ...
Read The Full Article On PotStockNews.com
Get the latest marijuana stock news, cannabis on stock news on PotStockNews
All content provided by Pot Stock News is subject to our Terms Of Use and Disclaimer.